摘要
Abstract
Objective To observe the best time and ef icacy and safety ef ects of recombinant human erythropoietin alpha (rhEPO)for the treatment of anemia of cancer.Methods 70 cases of patients, pathological y diagnosed as cancer accompanied by non myeloid anemia,were selected in our hospital.Hemoglobin (Hb)level of Pre chemotherapy patients were 100~120g/L.According to the dif erent rhEPO patients using time,they were divided into the early and late use group.Early use of group at the time of chemotherapy is given by subcutaneous injection of rhEPO,late in the experiment group Hb<90g/L when it was given by subcutaneous injection of rhEPO.For treatment during iron deficiency,the ef ect was not obvious in patients with 0.1g by fer ous succinate oral y,3 times a day.Two groups were observed before and after treatment in patients with Hb and the hematocrit(HCT)levels,compared two groups of patients with the treatment of early stage the occur ence of adverse reactions. Results The treatment of 0~4 weeks,5~8 weeks,9~12 weeks,Hb level of early use of group were(116.8±6.7)g/L,(120.3±8.2)g/L,(128.1±10.3)g/L,HCT levels were(0.37±0.09)and(0.39±0.06)and(0.41±0.04);Hb level of late use groups were (108.6±5.9)g/L,(107.3±9.9)g/L,(105±8.7)g/L,HCT levels were (0.31±0.03)and (0.29±0.05)and (0.27±0.01),the dif erence between groups was significant ( <0.05). During the period of treatment,the patients of two groups were no serious adverse reactions,the main adverse reactions were fever,rash,fatigue and decreased appetite,etc.Conclusion Chemotherapy given rhEPO injection can ef ectively improve the patients with Hb and Hct level of patients with anemia,improve,and drug adverse reaction is lower.关键词
重组人促红细胞生成素-α/癌性贫血/疗效/安全性Key words
Recombinant human erythropoietin alpha/Anemia of cancer/Ef icacy/Safety
